Clinical Trial: Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.
Brief Summary: The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.
Detailed Summary:
Sponsor: Ophthalmic Consultants of Boston
Current Primary Outcome: The primary outcome measures for safety and tolerability [ Time Frame: Mean change in visual acuity from baseline to 6 months & 12 months ]
Original Primary Outcome: The primary outcome measures for safety and tolerability
Current Secondary Outcome: The secondary outcome measures for efficacy [ Time Frame: Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA ]
Original Secondary Outcome: The secondary outcome measures for efficacy
Information By: Ophthalmic Consultants of Boston
Dates:
Date Received: November 1, 2006
Date Started: December 2005
Date Completion:
Last Updated: January 7, 2010
Last Verified: January 2010